Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2018

Open Access 01-12-2018 | Debate

Should heart age calculators be used alongside absolute cardiovascular disease risk assessment?

Authors: Carissa Bonner, Katy Bell, Jesse Jansen, Paul Glasziou, Les Irwig, Jenny Doust, Kirsten McCaffery

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Login to get access

Abstract

Background

National estimates of ‘heart age’ by government health organisations in the US, UK and China show most people have an older heart age than current age. While most heart age calculators are promoted as a communication tool for lifestyle change, they may also be used to justify medication when clinical guidelines advocate their use alongside absolute risk assessment. However, only those at high absolute risk of a heart attack or stroke are likely to benefit from medication, and it is not always clear how heart age relates to absolute risk. This article aims to: 1) explain how heart age calculation methods relate to absolute risk guidelines; 2) summarise research investigating whether heart age improves risk communication; and 3) discuss implications for the use of medication and shared decision making in clinical practice.

Main body

There is a large and growing number of heart age models and online calculators, but the clinical meaning of an older heart age result is highly variable. An older heart age result may indicate low, moderate or high absolute risk of a heart attack or stroke in the next 5-10 years, and the same individual may receive a younger or older heart age result depending on which calculator is used. Heart age may help doctors convey the need to change lifestyle, but it cannot help patients make an informed choice about medication to reduce CVD risk.

Conclusion

Interactive heart age tools may be helpful as a communication tool to initiate lifestyle change to reduce risk factors. However, absolute risk should be used instead of heart age to enable informed decision making about medication, to avoid unnecessary treatment of low risk people. Evidence-based decision aids that improve patient understanding of absolute risk should be considered as alternatives to heart age calculators for lifestyle and medication decisions.
Literature
3.
go back to reference Groenewegen KA, den Ruijter HM, Pasterkamp G, Polak JF, Bots ML, Peters SAE. Vascular age to determine cardiovascular disease risk: a systematic review of its concepts, definitions, and clinical applications. Eur J Prev Cardiol. 2016;23(3):264–74.CrossRefPubMed Groenewegen KA, den Ruijter HM, Pasterkamp G, Polak JF, Bots ML, Peters SAE. Vascular age to determine cardiovascular disease risk: a systematic review of its concepts, definitions, and clinical applications. Eur J Prev Cardiol. 2016;23(3):264–74.CrossRefPubMed
4.
go back to reference Bonner C, Jansen J, Newell BR, et al. Is the ‘heart age’ concept helpful or harmful compared to absolute cardiovascular disease risk? An experimental study. Med Decis Mak. 2015;35(8):967–78.CrossRef Bonner C, Jansen J, Newell BR, et al. Is the ‘heart age’ concept helpful or harmful compared to absolute cardiovascular disease risk? An experimental study. Med Decis Mak. 2015;35(8):967–78.CrossRef
5.
go back to reference Joint British Societies. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100:ii1–ii67.CrossRef Joint British Societies. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100:ii1–ii67.CrossRef
6.
go back to reference Montori VM, Brito JP, Ting HH. Patient-centered and practical application of new high cholesterol guidelines to prevent cardiovascular disease. JAMA. 2014;311(5):465–6.CrossRefPubMed Montori VM, Brito JP, Ting HH. Patient-centered and practical application of new high cholesterol guidelines to prevent cardiovascular disease. JAMA. 2014;311(5):465–6.CrossRefPubMed
7.
go back to reference Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ. 2012;344:e3502.CrossRefPubMed Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ. 2012;344:e3502.CrossRefPubMed
8.
9.
go back to reference Editorial. Statins for millions more? Lancet. 2014;383(9918):669. Editorial. Statins for millions more? Lancet. 2014;383(9918):669.
10.
go back to reference Goldacre BM. Statins are a mess: we need better data, and shared decision making. BMJ. 2014;348:g3306. Goldacre BM. Statins are a mess: we need better data, and shared decision making. BMJ. 2014;348:g3306.
11.
go back to reference Wells S, Kerr A, Eadie S, Wiltshire C, Jackson R. ‘Your heart Forecast’: a new approach for describing and communicating cardiovascular risk? Heart. 2010;96(9):708–13.CrossRefPubMed Wells S, Kerr A, Eadie S, Wiltshire C, Jackson R. ‘Your heart Forecast’: a new approach for describing and communicating cardiovascular risk? Heart. 2010;96(9):708–13.CrossRefPubMed
12.
go back to reference Cuende JI. Vascular age versus cardiovascular risk: clarifying concepts. Rev Esp Cardiol. 2016;69:243–6.CrossRefPubMed Cuende JI. Vascular age versus cardiovascular risk: clarifying concepts. Rev Esp Cardiol. 2016;69:243–6.CrossRefPubMed
13.
go back to reference Grover SA, Lowensteyn I, Joseph L, et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med. 2007;167(21):2296–303.CrossRefPubMed Grover SA, Lowensteyn I, Joseph L, et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med. 2007;167(21):2296–303.CrossRefPubMed
14.
go back to reference Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover SA. Can computerized risk profiles help patients improve their coronary risk? The results of the coronary health assessment study (CHAS). Prev Med. 1998;27(5, pt1):730–7.CrossRefPubMed Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover SA. Can computerized risk profiles help patients improve their coronary risk? The results of the coronary health assessment study (CHAS). Prev Med. 1998;27(5, pt1):730–7.CrossRefPubMed
15.
go back to reference Neufingerl N, Cobain MR, Newson RS. Web-based self-assessment health tools: who are the users and what is the impact of missing input information? J Med Internet Res. 2014;16(9):e215.CrossRefPubMedCentralPubMed Neufingerl N, Cobain MR, Newson RS. Web-based self-assessment health tools: who are the users and what is the impact of missing input information? J Med Internet Res. 2014;16(9):e215.CrossRefPubMedCentralPubMed
16.
go back to reference Yang Q, Zhong Y, Ritchey M. Cobain, et al. vital signs: predicted heart age and racial disparities in heart age among U.S. adults at the state level. MMWR Morb Mortal Wkly Rep. 2015;64(34):950–8.CrossRefPubMed Yang Q, Zhong Y, Ritchey M. Cobain, et al. vital signs: predicted heart age and racial disparities in heart age among U.S. adults at the state level. MMWR Morb Mortal Wkly Rep. 2015;64(34):950–8.CrossRefPubMed
17.
go back to reference Patel RS, Lagord C, Waterall J, Moth M, Knapton M, Deanfield JE. Online self-assessment of cardiovascular risk using the joint British societies (JBS3)-derived heart age tool: a descriptive study. BMJ Open. 2016;6(9):e011511.CrossRefPubMedCentralPubMed Patel RS, Lagord C, Waterall J, Moth M, Knapton M, Deanfield JE. Online self-assessment of cardiovascular risk using the joint British societies (JBS3)-derived heart age tool: a descriptive study. BMJ Open. 2016;6(9):e011511.CrossRefPubMedCentralPubMed
18.
go back to reference Shi R, Lan Y, Lu C, Yu W. Abstract 051: a feasibility study on 10-year CVD risk assessment as a primary prevention tool for cardiovascular disease. Circ Cardiovasc Qual Outcomes. 2017;10(Suppl 3):A051. Shi R, Lan Y, Lu C, Yu W. Abstract 051: a feasibility study on 10-year CVD risk assessment as a primary prevention tool for cardiovascular disease. Circ Cardiovasc Qual Outcomes. 2017;10(Suppl 3):A051.
19.
go back to reference D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(6):743–53.CrossRefPubMed D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(6):743–53.CrossRefPubMed
26.
go back to reference Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31:2351–8.CrossRefPubMed Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31:2351–8.CrossRefPubMed
27.
go back to reference Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016;37:2315–81.CrossRefPubMedCentralPubMed Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016;37:2315–81.CrossRefPubMedCentralPubMed
28.
go back to reference Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers AR. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365(9457):434–41.CrossRefPubMed Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers AR. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365(9457):434–41.CrossRefPubMed
29.
go back to reference Jackson R, Kerr A, Wells S. ‘Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?’ No, but we can improve risk communication metrics. Eur Heart J. 2017;38(20):1548–52.PubMed Jackson R, Kerr A, Wells S. ‘Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?’ No, but we can improve risk communication metrics. Eur Heart J. 2017;38(20):1548–52.PubMed
30.
go back to reference Lopez-Gonzalez AA, Aguilo A, Frontera M, et al. Effectiveness of the heart age tool for improving modifiable cardiovascular risk factors in a southern European population: a randomized trial. Eur J Prev Cardiol. 2015;22(3):389–96.CrossRefPubMed Lopez-Gonzalez AA, Aguilo A, Frontera M, et al. Effectiveness of the heart age tool for improving modifiable cardiovascular risk factors in a southern European population: a randomized trial. Eur J Prev Cardiol. 2015;22(3):389–96.CrossRefPubMed
31.
go back to reference Soureti A, Hurling R, Murray P, van Mechelen W, Cobain M. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil. 2010;17(5):519–23.CrossRefPubMed Soureti A, Hurling R, Murray P, van Mechelen W, Cobain M. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil. 2010;17(5):519–23.CrossRefPubMed
32.
go back to reference Witteman HO, Fuhrel-Forbis A, Wijeysundera HC, et al. Animated randomness, avatars, movement, and personalization in risk graphics. J Med Internet Res. 2014;16(3):294–313. (Multimedia Appendix 3)CrossRef Witteman HO, Fuhrel-Forbis A, Wijeysundera HC, et al. Animated randomness, avatars, movement, and personalization in risk graphics. J Med Internet Res. 2014;16(3):294–313. (Multimedia Appendix 3)CrossRef
33.
go back to reference Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.CrossRef Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.CrossRef
34.
go back to reference The Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384(9943):591–8.CrossRef The Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384(9943):591–8.CrossRef
35.
36.
go back to reference Bonner C, Jansen J, Newell BR, et al. I don't believe it, but I'd better do something about it: patient experiences of online heart age risk calculators. J Med Internet Res. 2014;16(5):e120.CrossRefPubMedCentralPubMed Bonner C, Jansen J, Newell BR, et al. I don't believe it, but I'd better do something about it: patient experiences of online heart age risk calculators. J Med Internet Res. 2014;16(5):e120.CrossRefPubMedCentralPubMed
37.
go back to reference Mann DM, Ponieman D, Montori VM, Arciniega J, McGinn T. The Statin choice decision aid in primary care: a randomized trial. Patient Educ Couns. 2010;80(1):138–40.CrossRefPubMed Mann DM, Ponieman D, Montori VM, Arciniega J, McGinn T. The Statin choice decision aid in primary care: a randomized trial. Patient Educ Couns. 2010;80(1):138–40.CrossRefPubMed
38.
go back to reference Trevena LJ, Zikmund-Fisher BJ, Edwards E, et al. Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak. 2013;13(S2):S7.CrossRefPubMedCentralPubMed Trevena LJ, Zikmund-Fisher BJ, Edwards E, et al. Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak. 2013;13(S2):S7.CrossRefPubMedCentralPubMed
39.
go back to reference Bonner C, McKinn S, Lau A, Jansen J, Doust J, Trevena L, McCaffery K. Heuristics and biases in cardiovascular disease prevention: How can we improve communication about risk, benefits and harms? Patient Education & Counseling. In press, available online 11 Dec 2017: https://doi.org/10.1016/j.pec.2017.12.003. Bonner C, McKinn S, Lau A, Jansen J, Doust J, Trevena L, McCaffery K. Heuristics and biases in cardiovascular disease prevention: How can we improve communication about risk, benefits and harms? Patient Education & Counseling. In press, available online 11 Dec 2017: https://​doi.​org/​10.​1016/​j.​pec.​2017.​12.​003.
40.
go back to reference Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.PubMed Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.PubMed
41.
go back to reference Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA Intern Med. 2016;316(19):1979–81. Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA Intern Med. 2016;316(19):1979–81.
Metadata
Title
Should heart age calculators be used alongside absolute cardiovascular disease risk assessment?
Authors
Carissa Bonner
Katy Bell
Jesse Jansen
Paul Glasziou
Les Irwig
Jenny Doust
Kirsten McCaffery
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0760-1

Other articles of this Issue 1/2018

BMC Cardiovascular Disorders 1/2018 Go to the issue